A detailed history of Avantax Advisory Services, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Avantax Advisory Services, Inc. holds 15,855 shares of EDIT stock, worth $54,065. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,855
Previous 14,511 9.26%
Holding current value
$54,065
Previous $107,000 30.84%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$4.67 - $7.28 $6,276 - $9,784
1,344 Added 9.26%
15,855 $74,000
Q1 2024

May 08, 2024

BUY
$7.03 - $11.07 $12,857 - $20,247
1,829 Added 14.42%
14,511 $107,000
Q4 2023

Feb 07, 2024

BUY
$6.25 - $11.11 $4,462 - $7,932
714 Added 5.97%
12,682 $128,000
Q3 2023

Nov 07, 2023

SELL
$6.92 - $9.31 $8,373 - $11,265
-1,210 Reduced 9.18%
11,968 $93,000
Q2 2023

Aug 11, 2023

BUY
$6.36 - $11.47 $83,812 - $151,151
13,178 New
13,178 $108,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $234M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Avantax Advisory Services, Inc. Portfolio

Follow Avantax Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Advisory Services, Inc. with notifications on news.